机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, 12 Jiankang St, Shijiazhuang 050011, Hebei, Peoples R China医技科室核医学科河北医科大学第四医院[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Hebei, Peoples R China[3]Shijiazhuang Huabei Pharmaceut Hosp, North China Med & Hlth Grp, Shijiazhuang, Hebei, Peoples R China
A 31-year-old man with multiple intrahepatic inflammatory myofibroblastoma tumor was referred to nuclear medicine department to assess its malignant potential. Multiple lesions in the liver exhibited Ga-68-FAPI uptake at different degrees. Instead, there was no abnormal F-18-FDG activity in the other hepatic lesions under the normal liver background except for the puncture site. This case reflects tumor heterogeneity of the disease and shows the potential value of Ga-68-FAPI PET/CT for the evaluation of hepatic inflammatory myofibroblastoma tumor.
基金:
Health Commission of Hebei Province in China [20160227]
第一作者机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, 12 Jiankang St, Shijiazhuang 050011, Hebei, Peoples R China[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Hebei Med Univ, Hosp 4, Dept Nucl Med, 12 Jiankang St, Shijiazhuang 050011, Hebei, Peoples R China[2]Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Hebei, Peoples R China[*1]Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang St, Chang’an District, Shijiazhuang, Hebei 050011, China.
推荐引用方式(GB/T 7714):
Li Tianyue,Liu Ziliang,Zhang Zhaoqi,et al.Multiple Intrahepatic Inflammatory Myofibroblastic Tumor on 68Ga-FAPI and 18F-FDG PET/CT[J].CLINICAL NUCLEAR MEDICINE.2023,48(12):E614-E616.doi:10.1097/RLU.0000000000004924.
APA:
Li, Tianyue,Liu, Ziliang,Zhang, Zhaoqi,Zhang, Jingmian&Zhao, Xinming.(2023).Multiple Intrahepatic Inflammatory Myofibroblastic Tumor on 68Ga-FAPI and 18F-FDG PET/CT.CLINICAL NUCLEAR MEDICINE,48,(12)
MLA:
Li, Tianyue,et al."Multiple Intrahepatic Inflammatory Myofibroblastic Tumor on 68Ga-FAPI and 18F-FDG PET/CT".CLINICAL NUCLEAR MEDICINE 48..12(2023):E614-E616